Company: DNLI
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001628280-25-008647
Chunk: 9

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 9
---
 the equity distribution agreement, under this prospectus supplement we may offer and sell shares of our common stock having an aggregate offering price of up to $400.0 million from time to time through or to the sales agents, acting as our agents or principals. The equity distribution agreement replaces our prior equity distribution agreement, dated February 28, 2022 with Goldman Sachs & Co. LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co. (the “prior equity distribution agreement”). As of the date of this prospectus, $400.0 million of shares of common stock remained available for sale under the prior equity distribution agreement. No sales will be made pursuant to the prior equity distribution agreement subsequent to the date of this prospectus supplement.

Our common stock is listed on The Nasdaq Global Select Market under the symbol “DNLI.” The last reported sale price of our common stock on February 25, 2025 was $19.20 per share.

Sales of our common stock, if any, under this prospectus supplement will be made in sales deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, in ordinary brokers’ transactions, to or through a market maker, on or through The Nasdaq Global Select Market or any other market venue where the securities may be traded, in the over-the-counter market, in privately negotiated transactions, or through a combination of any such methods of sale. The sales agents may also sell our common stock by any other method permitted by law. The sales agents are not required to sell any specific amount of securities but will act as our sales agents using commercially reasonable efforts consistent with their normal trading and sales practices, on mutually agreed terms between the sales agents and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

Under the equity distribution agreement, we may also sell common stock to the sales agents as principals for their own accounts, at a price to be agreed upon at the time of sale. If we sell common stock to the sales agents as principals, we will enter into a separate terms agreement with the sales agents, and we will describe the agreement in a separate prospectus supplement or pricing supplement.

The compensation to the sales agents for sales of common stock sold pursuant to the equity distribution will be an amount up to 3.00% of the gross proceeds of any shares of common stock sold under the equity distribution. In connection with the sale